Table 1.
Patient Characteristics
| Genotypic Tests, No.a |
|||||||||||||
| Baseline |
Follow-up |
Overall |
|||||||||||
| Patient ID | Sex | CD4 Cell Count, Cells/mm3 | HIV RNA Level, log10 Copies/mL | Subtype | GSSb | Therapy With Raltegravir | HIV RNA <50 Copies/mL at 24 wk | UDPS | Popc | UDPS | Popc | UDPS | Popc |
| 12 | F | 24 | 5.1 | B | 0 | 3TC, DRV/r, T20 | No | 1 | 1 | 5 | 4 | 6 | 5 |
| 27 | M | 231 | 3.6 | B | 1.75 | DRV/r, TDF, ETR | No | 1 | 1 | 1 | 1 | 2 | 2 |
| 49 | F | 21 | 4.5 | B | 2.5 | DRV/r, FTC, TDF | No | 1 | 1 | 1 | 1 | ||
| 56 | M | 1 | 5.5 | B | 0 | 3TC, DDI, DRV/r, T20 | No | 1 | 1 | 1 | 1 | ||
| 69 | F | 328 | 4.4 | B | 0 | 3TC, DRV/r | No | 1 | 1 | 2 | 2 | 3 | 3 |
| 80 | M | 2 | 4.7 | F | ND | 3TC, AZT, DRV/r | No | 1 | 1 | 1 | 1 | 2 | 2 |
| 81 | M | 83 | 5.3 | B | ND | 3TC, ETR | No | 1 | 1 | 1 | 1 | 2 | 2 |
| 84 | M | 14 | 5.5 | B | 0.5 | 3TC, MVC, TDF | No | 1 | 1 | 7 | 4 | 8 | 5 |
| 141 | M | 276 | 4.9 | B | 1 | 3TC, AZT, DRV/r, ETR | No | 1 | 1 | 1 | 1 | 2 | 2 |
| 142 | M | 7 | 5.7 | B | ND | DRV/r, ETR, FTC, T20, TDF | No | 1 | 1 | 1 | 1 | ||
| 145 | M | 480 | 5 | B | 0 | 3TC, DRV/r | No | 1 | 1 | 1 | 1 | 2 | 2 |
| 156 | F | 320 | 5.4 | B | 1.5 | EFV, LPV/r | No | 1 | 1 | 1 | 2 | 1 | |
| 162 | M | 192 | 5.1 | B | 2.5 | ETR, SQV/r | No | 1 | 1 | 2 | 3 | 1 | |
| 229 | F | 8 | 4.7 | B | 1.5 | DRV/r, ETR, FTC, TDF | No | 1 | 1 | 3 | 2 | 4 | 3 |
| 5 | F | 315 | 5.3 | F | 2.5 | DRV/r, ETR | Yes | 1 | 1 | 1 | 1 | ||
| 15 | M | 178 | 5.2 | B | 0 | DRV/r, FTC, MVC, TDF | Yes | 1 | 1 | 1 | 1 | ||
| 16 | M | 132 | 4.6 | B | 0.5 | 3TC, DRV/r, TDF | Yes | 1 | 1 | 1 | 1 | ||
| 45 | F | 106 | 5.7 | B | ND | 3TC, DRV/r, EFV | Yes | 1 | 1 | 1 | 1 | ||
| 57 | M | 105 | 5.3 | B | ND | DRV/r, FTC, TDF | Yes | 1 | 1 | 1 | 1 | ||
| 58 | M | 563 | 4 | B | 0.75 | DRV/r, FTC, TDF | Yes | 1 | 1 | 1 | 1 | ||
| 63 | M | 170 | 5.6 | B | 1.75 | DRV/r, FTC, TDF | Yes | 1 | 1 | 1 | 1 | ||
| 151 | M | 207 | 4.7 | B | ND | DRV/r, FTC, TDF | Yes | 1 | 1 | 1 | 1 | ||
| 155 | M | 11 | 5.7 | B | 1 | ETR, T20 | Yes | 1 | 1 | 1 | 1 | ||
| Total (n = 23) | Median: 170 (IQR, 21–276) | Median: 5.1 (IQR, 4.7–5.4) | Median: 1.0 (IQR, 0–1.75) | 23 | 23 | 25 | 16 | 48 | 40 | ||||
Abbreviations: 3TC, lamivudine; AZT, zidovudine; DDI, didanosine; DRV/r, darunavir/ritonavir boosted; ETR, etravirine; FTC, emtricitabine; GSS, genotype sensitive score; HIV, human immunodeficiency virus; IQR, interquartile range; MVC, maraviroc; ND, not determined; Pop, population; SQV/r, saquinavir/ritonavir boosted; T20, enfuvirtide; TDF, tenofovir; .UDPS, Ultra-Deep-454 Pyrosequencing.
UDPS and population sequencing were not available for patients at failure ID49, ID56, ID142 (because with HIV-RNA levels < 500 copies/ml) and for all patients with HIV-RNA levels < 50 copies at 24 week.
The GSS to optimized background therapy was calculated for patients with an available protease and reverse-transcriptase sequence at raltegravir baseline, according to the coadministration of protease inhibitors, nonnucleoside reverse-transcriptase inhibitors, and nucleoside reverse-transcriptase inhibitors, obtained by using the Rega 8.02 algorithm.
Population sequencing.